Novo Nordisk A/S (VIE:NNO2)

Market Cap	147.55B -62.3%
Revenue (ttm)	41.38B +6.4%
Net Income	13.72B +1.4%
EPS	3.08 +1.8%
Shares Out	n/a
PE Ratio	10.76
Forward PE	11.82
Dividend	1.56 (4.72%)
Ex-Dividend Date	Aug 15, 2025

Volume	284
Average Volume	8,013
Open	33.65
Previous Close	34.18
Day's Range	33.40 - 33.66
52-Week Range	30.81 - 76.71
Beta	n/a
RSI	36.63
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 69,150
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: NNO2

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK